<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0004026'>Monosomy</z:mp> 7 (Mo7) and <z:mpath ids='MPATH_336'>leukaemia</z:mpath> predisposition are associated with <z:e sem="disease" ids="C0340970" disease_type="Disease or Syndrome" abbrv="">Kostmann</z:e>'s disease (KD) </plain></SENT>
<SENT sid="1" pm="."><plain>The recent introduction of long-term recombinant HuG-CSF treatment in patients with KD, whilst showing significant reductions in infectious complications and improved quality of life, might also be associated with an increased risk of developing karyotypic abnormalities, <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a case of an identical twin with probable <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> KD who developed <z:hpo ids='HP_0001903'>anaemia</z:hpo>, Mo7/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at 18, 30 and 50 months respectively from starting r-metHuG-CSF (filgrastim) treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Further patient analyses are required to establish the natural history of KD and to determine what role, if any, filgrastim plays in altering the pathobiology of this disorder </plain></SENT>
</text></document>